Melphalan

證據等級: L5

預測適應症: 10 個

Melphalan: From Multiple Myeloma to Gonadal Germ Cell Tumor

One-Sentence Summary

Melphalan is a nitrogen mustard alkylating agent internationally established for multiple myeloma (and, in some jurisdictions, ovarian cancer). The TxGNN model predicts it may be effective for Gonadal Germ Cell Tumor, with 8 clinical trials and 4 publications currently supporting this direction — though only one trial and no publications are disease-specific.

Quick Overview

Item	Content
Original Indication	Multiple myeloma (established international indication; no ARTG-approved indication text is available — Melphalan is not currently marketed in Australia)
Predicted New Indication	Gonadal Germ Cell Tumor
TxGNN Prediction Score	99.77%
Evidence Level	L2
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in this evidence pack (data gap DG002). Based on known pharmacology, Melphalan is a bifunctional alkylating agent (nitrogen mustard derivative) that forms DNA interstrand crosslinks, producing cytotoxicity that is most pronounced in rapidly dividing cells — a property shared by germ cell tumours, which are among the most chemosensitive solid tumours known.

Melphalan already has an established role in high-dose chemotherapy conditioning regimens combined with autologous stem cell transplantation (ASCT), including as salvage therapy for relapsed, poor-prognosis germ-cell tumours. This gives the TxGNN prediction a direct clinical precedent rather than a purely computational association: the mechanistic rationale (alkylator activity against a highly chemosensitive tumour type) aligns with real-world high-dose chemotherapy practice.

The strongest supporting evidence is a Phase 2 trial (NCT00936936, n=64) studying high-dose chemotherapy — including melphalan — specifically for poor-prognosis relapsed germ-cell tumours. Most of the remaining trials are non-disease-specific ASCT-conditioning studies that include germ-cell tumour patients as part of a broader solid-tumour population, which supports feasibility and safety of the regimen but not disease-specific efficacy on its own.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00936936	Phase 2	Completed	64	Two cycles of high-dose chemotherapy (including melphalan) specifically for poor-prognosis relapsed germ-cell tumours — the only disease-specific trial in this set
NCT00003425	Phase 1/2	Completed	25	Escalating-dose melphalan with autologous stem cell support and amifostine cytoprotection in cancer patients (not disease-specific)
NCT00003926	Phase 1	Terminated	13	Amifostine cytoprotection with autologous stem cell transplant for high-risk/relapsed paediatric solid and brain tumours
NCT00638898	Phase 1	Completed	25	High-dose busulfan, melphalan and topotecan followed by autologous HSCT in advanced/recurrent tumours (not disease-specific)
NCT00536601	N/A	Completed	174	Pilot study of high-dose chemotherapy regimens ± total-body irradiation before autologous transplant, across haematologic malignancies and selected solid tumours
NCT00060255	Phase 2	Completed	451	Eight high-dose chemotherapy regimens ± total-body irradiation before autologous transplant, across haematologic malignancy and selected solid tumours
NCT01272817	N/A	Completed	36	Nonmyeloablative allogeneic HSCT using melphalan and cladribine (or total lymphoid irradiation) conditioning, across various haematologic conditions
NCT00002750	Phase 1	Completed	6	Intrathecal melphalan for recurrent neoplastic meningitis — different route and indication to systemic use in germ-cell tumours

Literature Evidence

PMID	Year	Type	Journal	Key Findings
13392619	1956	Cohort	Voprosy onkologii	Early clinical experience treating testicular seminoma and its metastases with sarcolysin (melphalan’s original name)
4270380	1973	Review	Oncology	Review of chemotherapy approaches for testicular germinal tumours
24913	1977	Review	The Urologic Clinics of North America	General review of seminoma management
14151951	1964	Cohort	Acta – Unio Internationalis Contra Cancrum	Effect of hormonal and alkylating drugs on pituitary FSH-stimulating function

Australia Market Information

No ARTG entries are currently registered — Melphalan is not marketed in Australia (total ARTG licences: 0).

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (alkylating agent, nitrogen mustard class)
Myelosuppression Risk	High — dose-limiting toxicity; established use in myeloablative high-dose regimens requiring autologous stem cell rescue, as seen throughout the trial evidence above
Emetogenicity Classification	Moderate to high (particularly with IV high-dose regimens used in ASCT conditioning)
Monitoring Items	Full blood count with differential, renal function, hepatic function, mucositis assessment
Handling Protection	Standard cytotoxic drug handling precautions apply (PPE, closed-system transfer devices where available)

Specific toxicity grading is not confirmed by product-level data in this pack — please refer to the Product Information (PI) warnings and precautions once available.

Safety Considerations

Please refer to the approved Product Information (PI) for safety information. Key warnings, contraindications and drug-drug interaction data were not available in this evidence pack (DG001, blocking severity), and Melphalan currently has no ARTG-registered PI in Australia.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: One disease-specific Phase 2 trial (NCT00936936, n=64) supports high-dose melphalan-containing chemotherapy in poor-prognosis relapsed germ-cell tumours, and the mechanistic rationale (alkylator activity against a highly chemosensitive tumour) is sound. However, most remaining trials are non-disease-specific ASCT-conditioning studies, and product-level safety/MOA data is missing.

To proceed, the following is needed:

Product Information / regulatory safety data (warnings, contraindications) — currently a blocking data gap (DG001)
Confirmed mechanism-of-action documentation (DG002)
Drug-drug interaction data (currently not found)
Clarification of the ARTG registration pathway, given Melphalan is not currently marketed in Australia
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.